Author

B. Zhang

Institutions: The University of Texas MD Anderson Cancer Center, University of Cologne, Shanghai Jiao Tong University, Sichuan University, Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Fudan University Shanghai Cancer Center, University Hospital Cologne

Observed institutions: The University of Texas MD Anderson Cancer Center, University of Cologne, Shanghai Jiao Tong University, Sichuan University, Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Fudan University Shanghai Cancer Center, University Hospital Cologne

OpenAlex ID: A5158706379

P1.231: Updated Peri-R-02: Outcomes of Neoadjuvant ICI-Based Therapy Versus Chemotherapy in Resectable Driver-Negative NSCLC

2026 · H. Zhong, Q. Chu, et al. · Journal of Thoracic Oncology

P2.138: Histomorphology-Virtual Transcriptomics Fusion Maps the Immune Landscape for Prognostic Stratification in Lung Cancer

2026 · Z. Huang, Z. Yan, et al. · Journal of Thoracic Oncology

MO11.01: Deep Driver Mutation Analysis, with/without TP53 in LUAD Using Next-Gen AI of HE Slide-Derived Morphology

2026 · B. Zhang, Y. Wang, et al. · Journal of Thoracic Oncology

EP12.22: Patient Characteristics, Treatment Patterns, and Safety of 1L Osimertinib+Ctx in EGFRm NSCLC: A Prospective, Real-World Study

2026 · B. Han, H. Zhong, et al. · Journal of Thoracic Oncology

EP12.12: First-Line Oral Vinorelbine Plus Furmonertinib in Refractory EGFR-mutated NSCLC: Safety Run-In Data From a Two-Cohort Study

2026 · B. Han, H. Zhong, et al. · Journal of Thoracic Oncology

OA14.03: Clinical Outcomes of the Phase III Lonestar Trial: Local Consolidation Therapy After Nivolumab Plus Ipilimumab in NSCLC

2026 · M. Altan, S. Gandhi, et al. · Journal of Thoracic Oncology

P1.144: Updated Results From the OSTAR Trial: Efficacy and Safety of Adjuvant Osimertinib in High-Risk Stage I EGFRm NSCLC After R0 Resection

2026 · C. Chen, J. Xie, et al. · Journal of Thoracic Oncology

P2.341: A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

2026 · B. Zhang, Y. wang, et al. · Journal of Thoracic Oncology

P2.354: Surufatinib Plus Chemotherapy Versus Surufatinib in Patients With Thoracic Neuroendocrine Tumor: A Randomized, Phase II Study

2026 · Y. Zhang, H. Zhong, et al. · Journal of Thoracic Oncology

EP06.28: Perioperative Discordance of Genomic Alterations and PD-L1 Expression in Resectable Stage I-III Non-Small Cell Lung Cancer

2026 · R. Tan, B. Zhang, et al. · Journal of Thoracic Oncology

EP03.12: The Resistance Mechanism and Genomic Profile of Egfrm NSCLC Patients Progressed on 1L Osimertinib+Ctx (SURPASS Study)

2026 · Y.L. Lou, S. Li, et al. · Journal of Thoracic Oncology

MO15.07: Subcutaneous (SC) Tarlatamab in Patients W/ Extensive-Stage Small Cell Lung Cancer (ES-SCLC): DeLLphi-308 Ph 1B Study

2026 · P. Rocha, L. Paz-Ares, et al. · Journal of Thoracic Oncology

P3.272: Acquired BRAF V600E as Bypass Resistance to EGFR TKIs in EGFR-mutant NSCLC: A Global Multicenter Cohort Study

2026 · Y. Xia, W. Xu, et al. · Journal of Thoracic Oncology

P3.208: Dacomitinib in Advanced NSCLC With Uncommon EGFR Mutations: A Biomarker Analysis of a Phase II Study

2026 · B. Zhang, C. Shi, et al. · Journal of Thoracic Oncology

Works count: 14

Citation count:

H-index:

I10-index: